A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Mavik Patient, Information, Instructions - Trandolapril
Mavik Patient, Information, Instructions - Trandolapril
PATIENT INFORMATION
Angioedema:
Angioedema, including laryngeal edema, may occur at any time
during treatment with ACE inhibitors, including MAVIK. Patients should be so
advised and told to report immediately any signs or symptoms suggesting angioedema
(swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing
or breathing) and to stop taking the drug until they have consulted with their
physician. (See WARNINGS and ADVERSE
REACTIONS.)
Symptomatic Hypotension:
Patients should be cautioned that light-headedness can occur,
especially during the first days of MAVIK therapy, and should be reported to
a physician. If actual syncope occurs, patients should be told to stop taking
the drug until they have consulted with their physician (See WARNINGS.)
All patients should be cautioned that inadequate fluid intake, excessive perspiration,
diarrhea, or vomiting, resulting in reduced fluid volume, may precipitate an
excessive fall in blood pressure with the same consequences of light-headedness
and possible syncope.
Patients planning to undergo any surgery and/or anesthesia
should be told to inform their physician that they are taking an ACE inhibitor
that has a long duration of action.
Hyperkalemia:
Patients should be told not to use potassium supplements or
salt substitutes containing potassium without consulting their physician. (See
PRECAUTIONS.)
Neutropenia:
Patients should be told to report promptly any indication of
infection (e.g., sore throat, fever) which could be a sign of neutropenia.
Pregnancy:
Female patients of childbearing age should be told about the
consequences of second- and third-trimester exposure to ACE inhibitors, and
they should also be told that these consequences do not appear to have resulted
from intrauterine ACE-inhibitor exposure that has been limited to the first
trimester. These patients should be asked to report pregnancies to their physicians
as soon as possible. NOTE: As with many other drugs, certain advice to patients
being treated with MAVIK is warranted. This information is intended to aid in
the safe and effective use of this medication. It is not a disclosure of all
possible adverse or intended effects.
top
